Association of breast cancer risk loci with breast cancer survival

International Journal of Cancer

Volumn 137, Issue 12, 2015, Pages 2837-2845

  Barrdahl, Myrto ^a   Canzian, Federico ^a   Lindström, Sara ^b   Shui, Irene ^b   Black, Amanda ^c   Hoover, Robert N ^c   Ziegler, Regina G ^c   Buring, Julie E ^d,e   Chanock, Stephen J ^c,f   Diver, W Ryan ^g   Gapstur, Susan M ^g   Gaudet, Mia M ^g   Giles, Graham G ^h,i   Haiman, Christopher ^j   Henderson, Brian E ^j   Hankinson, Susan ^b,e,k   Hunter, David J ^b   Joshi, Amit D ^b   Kraft, Peter ^b   Lee, I Min ^b,d   Le Marchand, Loic ^l   Milne, Roger L ^h,i   Southey, Melissa C ^m   Willett, Walter ^b   Gunter, Marc ⁿ   Panico, Salvatore ^o   Sund, Malin ^p   Weiderpass, Elisabete ^q,r,s,t   Sánchez, María José ^u,v   Overvad, Kim ^w   Dossus, Laure ^x,y,z   Peeters, Petra H ^aa,ab   Khaw, Kay Tee ^ac   Trichopoulos, Dimitrios ^b,ad,ae   Kaaks, Rudolf ^a   Campa, Daniele ^a   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g AMERICAN CANCER SOCIETY   (United States)

^h CANCER EPIDEMIOLOGY CENTRE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k UNIVERSITY OF MASSACHUSETTS   (United States)

^l UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^m UNIVERSITY OF MELBOURNE   (Australia)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

^o Dipartimento di Medicina Clinica e Chirurgia   (Italy)

^p UMEÅ UNIVERSITY   (Sweden)

^q UNIVERSITY OF TROMSØ   (Norway)

^r CANCER REGISTRY OF NORWAY   (Norway)

^s KAROLINSKA INSTITUTE   (Sweden)

^t FOLKHÄLSAN RESEARCH CENTER   (Finland)

^u ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^v CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^w AARHUS UNIVERSITY   (Denmark)

^x INSERM   (France)

^y CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^z IGR   (France)

^aa UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ab IMPERIAL COLLEGE LONDON   (United Kingdom)

^ac UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ad BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^ae HELLENIC HEALTH FOUNDATION   (Greece)

more..

Author keywords

BPC3; breast cancer; meta analysis; SNP; survival

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CDKN1C GENE; COHORT ANALYSIS; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LSP1 GENE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TNRC9 GENE; TREATMENT RESPONSE; BREAST TUMOR; FEMALE; GENE LOCUS; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

BREAST NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84943660554     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29446     Document Type: Article

References (50)

1. Michaelson JS, Silverstein M, Sgroi D, et al., The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003; 98: 2133-43
2. Shek LL, Godolphin W,. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 1988; 48: 5565-9
3. Olsson A, Sartor H, Borgquist S, et al., Breast density and mode of detection in relation to breast cancer specific survival: a cohort study. BMC Cancer 2014; 14: 229
4. Hartman M, Lindstrom L, Dickman PW, et al., Is breast cancer prognosis inherited? Breast Cancer Res 2007; 9: R39
5. Azzato EM, Lee AJ, Teschendorff A, et al., Common germ-line polymorphism of C1QA and breast cancer survival. Br J Cancer 2010; 102: 1294-9
6. Udler MS, Azzato EM, Healey CS, et al., Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 2009; 125: 2687-96
7. Azzato EM, Tyrer J, Fasching PA, et al., Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. JNCI 2010; 102: 650-62
8. Shi H, Bevier M, Johansson R, et al., Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome. Breast Cancer Res Treat 2011; 130: 905-16
9. Yu CP, Yu JC, Sun CA, et al., Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 2008; 107: 95-102
10. Fasching PA, Pharoah PD, Cox A, et al., The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet 2012; 21: 3926-39
11. Hunter DJ, Riboli E, Haiman CA, et al., A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005; 5: 977-85
12. Riboli E, Hunt KJ, Slimani N, et al., European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 2002; 5: 1113-24
13. Giles GG, English DR,. The Melbourne Collaborative Cohort Study. IARC Sci Publ 2002; 156: 69-70
14. Colditz GA, Hankinson SE,. The nurses' health study: lifestyle and health among women. Nat Rev Cancer 2005; 5: 388-96
15. Rexrode K, Lee I, Cook N, et al., Baseline characteristics of participants in the women's health study. Womens Health Gend Based Med 2000; 9: 19-27
16. Calle EE, Rodriguez C, Jacobs EJ, et al., The American cancer society cancer prevention study II nutrition cohort: rationale, study design, and baseline characteristics. Cancer 2002; 94: 2490-501
17. Hayes RB, Reding D, Kopp W, et al., Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21: 349-55
18. Kolonel LN, Henderson BE, Hankin JH, et al., A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000; 151: 346-57
19. Campa D, Kaaks R, Le March L, et al., Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. JNCI 2011; 103: 1252-63
20. Collett D., Modelling survival data in medical research. London: Chapman & Hall/Crc, 2003. 144
21. Gao X, Starmer J, Martin ER,. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 2008; 32: 361-9
22. Grundberg E, Small KS, Hedman AK, et al., Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet 2012; 44: 1084-9
23. Consortium GT,. The Genotype-tissue expression (GTEx) project. Nat Genet 2013; 45: 580-5
24. Boyle AP, Hong EL, Hariharan M, et al., Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012; 22: 1790-7
25. Ward LD, Kellis M,. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40: D930-4
26. Shapiro GI,. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-83
27. Matsuoka S, Edwards MC, Bai C, et al., p57KIP2, a structurally distinct member of the p21CIP1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995; 9: 650-62
28. Larson PS, Schlechter BL, King CL, et al., CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 2008; 8: 68
29. Yang X, Karuturi RK, Sun F, et al., CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PloS One 2009; 4: e5011
30. Rodriguez BA, Weng YI, Liu TM, et al., Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis 2011; 32: 812-21
31. Woolcott CG, Maskarinec G, Haiman CA, et al., Association between breast cancer susceptibility loci and mammographic density: the multiethnic cohort. Breast Cancer Res 2009; 11: R10
32. Fernandez-Navarro P, Pita G, Santamarina C, et al., Association analysis between breast cancer genetic variants and mammographic density in a large population-based study (determinants of density in mammographies in spain) identifies susceptibility loci in TOX3 gene. Eur J Cancer 2013; 49: 474-81
33. Vachon CM, Scott CG, Fasching PA, et al., Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev 2012; 21: 1156-66
34. Gierach GL, Ichikawa L, Kerlikowske K, et al., Relationship between mammographic density and breast cancer death in the breast cancer surveillance consortium. JNCI 2012; 104: 1218-27
35. Yaghjyan L, Colditz GA, Rosner B, et al., Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the time since the mammogram. Cancer Epidemiol Biomarkers Prev 2013; 22: 1110-7
36. Maskarinec G, Pagano IS, Little MA, et al., Mammographic density as a predictor of breast cancer survival: the multiethnic cohort. Breast Cancer Res 2013; 15: R7
37. Thomas G, Jacobs KB, Kraft P, et al., A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009; 41: 579-84
38. Siddiq A, Couch F, Chen G, et al., A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet 2012; 21: 5373-84
39. Sueta A, Ito H, Kawase T, et al., A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat 2012; 132: 711-21
40. Cox A, Dunning AM, Garcia-Closas M, et al., A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007; 39: 352-8
41. Stacey SN, Manolescu A, Sulem P, et al., Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007; 39: 865-9
42. Ahmed S, Thomas G, Ghoussaini M, et al., Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009; 41: 585-90
43. Stacey SN, Manolescu A, Sulem P, et al., Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008; 40: 703-6
44. Haiman CA, Chen GK, Vachon CM, et al., A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011; 43: 1210-4
45. Easton DF, Pooley KA, Dunning AM, et al., Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93
46. Turnbull C, Ahmed S, Morrison J, et al., Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010; 42: 504-7
47. Kim HC, Lee JY, Sung H, et al., A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the seoul breast cancer study. Breast Cancer Res 2012; 14: R56
48. Antoniou AC, Kuchenbaecker KB, Soucy P, et al., Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 2012; 14: R33
49. Prentice RL, Huang Y, Hinds DA, et al., Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 3079-85
50. Lambrechts D, Truong T, Justenhoven C, et al., 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat 2012; 33: 1123-32